Bank of Montreal’s Neuropace NPCE Stock Holding History

Bank of Montreal’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-32,223	Closed	-$246K	–	4122
2024 Q2	$246K	Buy	+32,223	New	+$325K	﹤0.01%	2862

Other funds holding NPCE

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

KLP

Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Bank of Montreal's NPCE Position: Q3 2024 in Review

Bank of Montreal sold out of Neuropace (NPCE) in Q3 2024, closing a stake of 32,223 shares — an estimated $246K sold.

Bank of Montreal first reported a position in NPCE in Q2 2024 and held it in 1 quarter. The position peaked at $246K in Q2 2024. 48 funds tracked by Wall St. Rank hold NPCE as of Q3 2024.

Bank of Montreal reported no remaining Neuropace position as of Q3 2024 after selling out during the quarter.
Bank of Montreal sold 32,223 Neuropace shares in Q3 2024, an estimated $246K.
Bank of Montreal first reported a position in Neuropace in Q2 2024 and held it in 1 quarter.
Bank of Montreal's Neuropace position peaked at $246K in Q2 2024.
48 funds tracked by Wall St. Rank held Neuropace as of Q3 2024.

Based on Bank of Montreal's 13F filing for Q3 2024, filed 13 Nov 2024.